The establishment of reference intervals for biomarkers in healthy populations relies on large-scale, standardized cohort data. However, current baseline data for hematology, liver and kidney function, and multi-omics (genomics, transcriptomics, proteomics, and metabolomics) in Chinese healthy populations are constrained by significant regional disparities and insufficient sample sizes, limiting the development of early disease screening markers. To address these challenges, this study aims to: (1) establish a comprehensive database for hematology and liver/kidney function indicators; (2) construct a multi-omics database using blood and sputum samples; and (3) explore the correlations among multi-omics indicators and their associations with demographic characteristics.

Inclusion Criteria:

1. Age: 18 - 65 years old, gender not restricted;
2. No clear history of chronic diseases (hypertension, diabetes, cardiovascular and cerebrovascular diseases, chronic liver and kidney diseases, tumors, etc.);
3. No infection history in the past 3 months (fever, cough, sore throat, etc.);
4. No use of antibiotics, hormones, immunosuppressants, etc. within the past 1 month;
5. Voluntarily sign the informed consent form and cooperate to complete the follow-up.

Exclusion Criteria:

1. Abnormal laboratory indicators (ALT/AST > 2 times the upper limit of normal value, Cr > upper limit of normal value, main indicators of blood routine test are abnormal and have clinical significance);
2. Pregnant or lactating women;
3. Recent (within 3 months) history of surgery, trauma or blood transfusion;
4. Mental illness or cognitive impairment that makes it impossible to cooperate with the research.

healthy populations

Due to concerns over patient privacy and confidentiality issues, the individual patient data (IPD) cannot be shared.